Clinical Trial Update: A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating epitope-enhanced TARP peptide vaccines with TARP peptide-pulsed dendritic cells in stage D0 prostate cancer; completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Epitope-enhanced TARP peptide vaccine
• TARP peptide-pulsed dendritic cells

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostate Specific Antigens, Prostate Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2022-10-12